{
    "clinical_study": {
        "@rank": "16803", 
        "arm_group": {
            "arm_group_label": "Skintel", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to improve the treatment guidelines for the Elite+ by\n      determining the maximum safe settings for skin and correlate them to measurement of Melanin\n      Index (MI) (MI)."
        }, 
        "brief_title": "Skintel Integration Study", 
        "condition": "Skin Type From I-VI on Non-hair Bearing Skin", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years and older\n\n          -  Able to read, understand, and sign the Informed Consent Form\n\n          -  Willing and able to comply with all study requirements\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to light in the near infrared wavelength region\n\n          -  Sun-damaged skin (treatment contraindicated with Alex laser only)\n\n          -  Unprotected sun exposure (for Alex laser within four weeks of treatment; for\n\n          -  Nd:YAG laser within one week of treatment), including the use of tanning beds or\n\n          -  tanning products, such as creams, lotions and sprays\n\n          -  Take medication which is known to increase sensitivity to sunlight\n\n          -  Seizure disorders triggered by light\n\n          -  Take anticoagulants\n\n          -  Take or have taken oral isotretinoin, such as Accutane\u00ae, within the last six months\n\n          -  Take medication that alters the wound-healing response\n\n          -  History of healing problems or history of keloid formation\n\n          -  Active localized or systemic infection, or an open wound in area being treated\n\n          -  Significant systemic illness or an illness localized in area being treated\n\n          -  History of skin cancer or suspicious lesions\n\n          -  Lupus\n\n          -  Have received or are receiving or gold therapy\n\n          -  Pregnancy, planning on becoming pregnant or have been pregnant recently"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130609", 
            "org_study_id": "CYN13-SkinTel-Elite+-01"
        }, 
        "intervention": {
            "arm_group_label": "Skintel", 
            "intervention_name": "Skintel", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 1, 2014", 
        "number_of_arms": "1", 
        "official_title": "Skintel Integration Study for Use With the Elite+ Laser System", 
        "overall_official": {
            "last_name": "Sean Doherty, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "improve the treatment guidelines for the Elite+ by determining the maximum safe settings for skin and correlate them to measurement of Melanin Index", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}